Next Science Limited (ASX:NXS)


right-arrow Created with Sketch. -0.02 (-1.79%)
MCAP $217.7M
Last trade 16.10pm 21/01/2022 20mins delayed

Latest Announcements

09/11/2021NXSNext Science Limited
08/11/2021 Price SensitivePSNXSNext Science Limited
01/11/2021 Price SensitivePSNXSNext Science Limited
01/11/2021 Price SensitivePSNXSNext Science Limited
28/10/2021 Price SensitivePSNXSNext Science Limited
19/10/2021NXSNext Science Limited
06/09/2021NXSNext Science Limited
06/09/2021NXSNext Science Limited

Company Overview

Next Science Limited is an Australia-based medical technology company. The Company's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The Company's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.

NXS in the news

Next Science (NXS) has seen its XPERIENCE Surgical Solution cleared by Australia’s…
Next Science’s (NXS) XPerience no rinse antimicrobial solution has been cleared by…
Biotech company Next Science (NXS) has received CE Mark approval for its…
Biotech company Next Science (NXS) has completed its oversubscribed share purchase plan…

Search Previous Announcements